title: The effect on joint fluid concentration of neuropeptide Y by intra-articular injection of glucocorticoid in temporomandibular joint arthritis.
abstract: Twenty-two patients (29 joints) with temporomandibular joint (TMJ) arthritis of specific or unspecific nature were given one intra-articular glucocorticoid (GC) injection. The effect on subjective symptoms and clinical signs in the craniomandibular system and on joint aspirate concentration of neuropeptide Y-like immunoreactivity (NPY-LI) was evaluated at follow-up visits 2-3 or 4-6 weeks after treatment. In the patients with specific inflammatory joint disease the treatment resulted in an improvement of symptoms and clinical signs and in a reduction in the TMJ level of NPY-LI 2-3 weeks after treatment. In the patients with unspecific inflammatory joint disease there was also an improvement in the clinical variables and a reduction in the NPY-LI level after 2-3 weeks, but not on a statistically significant level. The results of this study show that intra-articular GC treatment causes a short-term decrease of the TMJ fluid level of NPY-LI in patients with specific inflammatory joint disease, while symptoms and signs improve.
authors.affiliation: Department of Clinical Oral Physiology/Center for Clinical Oral Science, Karolinska Institutet, Huddinge, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Alstergren
authors.forename: A
authors.initials: A
authors.lastname: Appelgren
authors.forename: B
authors.initials: B
authors.lastname: Appelgren
authors.forename: S
authors.initials: S
authors.lastname: Kopp
authors.forename: T
authors.initials: T
authors.lastname: Lundeberg
authors.forename: E
authors.initials: E
authors.lastname: Theodorsson
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy* / Q000503:physiopathology; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000503:physiopathology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007270:Injections, Intra-Articular; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009478:Neuropeptide Y / Q000032:analysis* / Q000187:drug effects; D010147:Pain Measurement; D017288:Pain Threshold; D011677:Punctures; D013582:Synovial Fluid / Q000737:chemistry* / Q000187:drug effects; D013705:Temporomandibular Joint Disorders / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000893:Anti-Inflammatory Agents; D009478:Neuropeptide Y; D008775:Methylprednisolone